title: Partial liquid ventilation decreases serum tumor necrosis factor-alpha concentrations in a rat acid aspiration lung injury model.
abstract: OBJECTIVE
  To examine the hypothesis that partial liquid ventilation (PLV) with perfluorocarbon would decrease serum tumor necrosis factor-alpha concentrations in a rat acid aspiration lung injury model.
  
  
  METHODS
  Prospective, controlled animal study.
  
  
  METHODS
  Research laboratory in a university setting.
  
  
  METHODS
  Male Sprague-Dawley rats.
  
  
  METHODS
  Treatment with intratracheal perflubron or control mechanical ventilation beginning 30 mins after acid aspiration.
  
  
  RESULTS
  PLV with perfluorocarbon compared with control ventilation resulted in significantly greater mean arterial blood pressures at 3 and 4 hrs and greater arterial Po2 at all times. Serum tumor necrosis factor-alpha at 2, 3, and 4 hrs was significantly less than that observed in the control group (4-hr values: 80+/-64 pg/mL vs. 658+/-688 pg/mL; p<.05), although no significant difference in tracheal fluid tumor necrosis factor-alpha concentrations (1425+/-1347 pg/mL vs. 2219+/-1933 pg/mL) was found.
  
  
  CONCLUSIONS
  We conclude that the effects of PLV with perfluorocarbon can extend beyond improvements in pulmonary physiology and that PLV may be beneficial in reducing systemic sequelae of acute lung injury and inflammation.
authors.affiliation: Department of Medicine, Mount Sinai Hospital, Samuel Lunenfeld Research Institute, Toronto, ON, Canada.
authors.forename: K
authors.initials: K
authors.lastname: Kawamae
authors.forename: G
authors.initials: G
authors.lastname: Pristine
authors.forename: D
authors.initials: D
authors.lastname: Chiumello
authors.forename: L N
authors.initials: LN
authors.lastname: Tremblay
authors.forename: A S
authors.initials: AS
authors.lastname: Slutsky
mesh_terms: D000818:Animals; D001784:Blood Gas Analysis; D001794:Blood Pressure / Q000187:drug effects; D015984:Causality; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005466:Fluorocarbons / Q000494:pharmacology / Q000627:therapeutic use*; D006842:Hydrocarbons, Brominated; D006851:Hydrochloric Acid; D007249:Inflammation; D007322:Instillation, Drug; D008297:Male; D010100:Oxygen / Q000097:blood; D011015:Pneumonia, Aspiration / Q000139:chemically induced / Q000150:complications*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012121:Respiration, Artificial / Q000379:methods*; D012128:Respiratory Distress Syndrome / Q000097:blood / Q000209:etiology* / Q000276:immunology / Q000628:therapy*; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects* / Q000378:metabolism*
chemical_list: D005466:Fluorocarbons; D006842:Hydrocarbons, Brominated; D014409:Tumor Necrosis Factor-alpha; C003072:perflubron; D006851:Hydrochloric Acid; D010100:Oxygen